An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)
Abstract Background The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This has likely resulted in a greater number of approvals and possibly drugs coming to market faster, but it is unknown whether these drugs a...
| Published in: | Cancer Medicine |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-04-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7190 |